CRO Engaged to Advance Stabl-Im Phase 1 Trial

Summary by 6ix AI

Stabl-Im is designed to visualize tumors using MRI-based functional imaging without radioactive tracers. The planned trial will assess the safety and tolerability of Stabl-Im in healthy volunteers following oral dosing. This engagement marks a significant milestone in TrivarX's strategy to progress Stabl-Im toward clinical development and commercialization.

Written by 6ix AI from the company’s filing. How 6ix writes summaries